Uppsala, Sweden – 15 February 2023 – Biotage AB (publ) (“Biotage”) has entered into an agreement to acquire Astrea Bioseparations (“Astrea”), a high-growth chromatography solutions provider from Gamma...
.png)
Tomas Blomquist, President and CEO: Even though the end of the year was less satisfactory than we would have wanted, I can still say that 2022 was the best year in our 25-year history. Biotage grew ra...
Doubling the company’s footprint in Silicon Valley, a hot spot for the promising Biologics and Advanced Therapeutics area, is a testament to Biotage’s commitment and priority to continuously invest an...
Funded by academia, Vinnova and industry, a five-year multi-disciplinary collaboration has been launched to improve efficiency in production methods for adeno-associated virus (AAV) based gene therapi...
Biotage has launched the new Biotage® Selekt Enkel Flash Purification System, a new member of the Selekt family of instruments. Maintaining the small footprint, powerful interface, quality and robustn...
Biotage has launched the Biotage® Extrahera™ HV-5000, an automated workstation dedicated to column-based sample preparation that is able to aspirate and dispense high volume samples. The system mainta...
Biotage have published their annual report for 2021 giving end of year results for the entire organisation.
Plasmids are the common starting material for viral vectors, recombinant proteins, mRNA and DNA vaccines. With the rapid growth of interest in cell therapy, gene therapy and advanced therapeutics, the...
The recent global pandemic has illustrated that the development of smarter healthcare is a global need, as acknowledged by the U.N.’s sustainable development program. Biotage has recognized this trend...
Biotage AB has acquired ATDBio and strengthened its position in DNA and RNA Oligonucleotide synthesis and purification.
